Inozyme Pharma Inc
Company Profile
Business description
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Contact
321 Summer Street
Suite 400
Boston MA 02210
USAT: +1 857 330-4340
E: axel.bolte@inozyme.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
59
Stocks News & Analysis
stocks
2 ASX shares to avoid after results
stocks
Strong results from IPO bolter not enough to change our view
stocks
No sign of AI slowdown for Nvidia
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
---|---|---|---|
All Ordinaries | 8,263.60 | 27.70 | -0.33% |
CAC 40 | 7,640.95 | 63.28 | 0.84% |
DAX 40 | 18,912.57 | 130.28 | 0.69% |
Dow JONES (US) | 41,332.89 | 241.47 | 0.59% |
FTSE 100 | 8,379.64 | 35.79 | 0.43% |
HKSE | 17,786.32 | 93.87 | 0.53% |
NASDAQ | 17,536.69 | 19.34 | -0.11% |
Nikkei 225 | 38,362.53 | 9.23 | -0.02% |
NZX 50 Index | 12,353.61 | 116.99 | -0.94% |
S&P 500 | 5,594.52 | 2.34 | 0.04% |
S&P/ASX 200 | 8,045.10 | 26.30 | -0.33% |
SSE Composite Index | 2,823.11 | 14.32 | -0.50% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
---|---|---|---|
Red 5 Ltd RED | 0.32 | 0.05 | -12.33% |
Latin Resources Ltd LRS | 0.21 | 0.00 | 0.00% |
Imugene Ltd IMU | 0.06 | 0.01 | 9.26% |
Zip Co Ltd ZIP | 2.28 | 0.10 | -4.20% |
Pilbara Minerals Ltd PLS | 2.91 | 0.09 | -3.00% |
Telstra Group Ltd TLS | 3.91 | 0.01 | 0.26% |
Energy Resources of Australia Ltd ERA | 0.01 | 0.00 | -14.29% |
South32 Ltd S32 | 3.10 | 0.02 | 0.65% |
Vicinity Centres VCX | 2.20 | 0.03 | 1.38% |
Aurizon Holdings Ltd AZJ | 3.38 | 0.06 | 1.81% |